0001209191-19-053739.txt : 20191021 0001209191-19-053739.hdr.sgml : 20191021 20191021193146 ACCESSION NUMBER: 0001209191-19-053739 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191017 FILED AS OF DATE: 20191021 DATE AS OF CHANGE: 20191021 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Leber Laura CENTRAL INDEX KEY: 0001649191 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51541 FILM NUMBER: 191160415 MAIL ADDRESS: STREET 1: C/O GENOMIC HEALTH, INC. STREET 2: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-10-17 0 0001131324 GENOMIC HEALTH INC GHDX 0001649191 Leber Laura 301 PENOBSCOT DR. REDWOOD CITY CA 94063 0 1 0 0 Chief Communication Officer Common Stock 2019-03-11 5 G 0 E 275 0.00 D 13420 D Common Stock 2019-10-17 4 M 0 13183 22.98 A 26919 D Common Stock 2019-10-17 4 S 0 13183 70.942 D 13736 D Employee Stock Option (right to buy) 22.98 2019-10-17 4 M 0 13183 0.00 D 2021-01-27 Common Stock 13183 0 D Includes an aggregate of 9,384 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 14, 2018. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Represents weighted average sale price. Actual sale prices ranged from $70.71 to $71.135. The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter. /s/ Jason W. Radford, Attorney-in-fact 2019-10-21